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products among internal and/or external stakeholders, despite increasing use of 
PRO tools in regulatory studies 3) Maintenance of motivation and understanding 
of the study procedures in relevant healthcare professionals throughout the study 
period Key elements for best practices would include: 1) Strategize recruitment 
of physicians depending on their environment and resources available: general 
practitioners vs. hospital physicians 2) Deepen the understanding of the value of 
PRO assessments and contents of PRO questionnaires among internal/external 
stakeholders 3) Reinforce cross-functional collaboration in order to accelerate site 
recruitment, patient enrollment and the return of patient surveys We will further 
discuss the above difficulties during the planning and implementation phases of 
PMS with a PRO survey, as well as best practices based on our experience so far in 
Japan. These considerations and experiences will highlight important implications 
in conducting a PRO survey in PMS as a valuable opportunity to obtain real-world 
patient-relevant data in elderly patients immediately after a new product is avail-
able in the market.
PRM260
A Cost-EffECtivE EnhAnCEd REtRosPECtivE obsERvAtionAl study 
MEthodology to CAPtuRE EConoMiC buRdEn EvidEnCE in A RARE 
disEAsE using non-tubERCulous MyCobACtERiA infECtion As A ModEl
Gallagher JR1, McDermott KJ2, Risebrough N3, Heap KJ1, Watch J4
1Clarity Pharma Research, LLC, SPARTANBURG, SC, USA, 2Insmed Incorporated, Bridgewater, NJ, 
USA, 3ICON plc, Toronto, ON, Canada, 4ICON plc, Dublin 18, Ireland
Objective: Gaining adequate market access and reimbursement can be particu-
larly challenging for orphan drugs. Barriers include inadequate real world data 
on the disease’s epidemiology and its burden of illness. We deployed a unique 
combination of methodologies used in a multi-layered observational data capture 
approach to collect de-identified, publication-worthy clinical and resource utiliza-
tion data in a probability sample of patients with a rare disease (pulmonary non-
tuberculosis mycobacteria [PNTM]). We combine a new methodology (“blinded 
physician proportion survey”) with a new use of an old methodology (Delphi expert 
survey). MethOds: First-round studies in France, Germany, Italy, Spain, and the 
United Kingdom consisted of a “blinded physician specialty proportion” survey to 
determine the probability of physician selection by specialty (2,585 participating 
physicians), a nationally representative chart review with participating physi-
cians to determine target patients by region (619 physicians – 1,429 patients) and a 
Delphi study (an anonymous collaborative estimating methodology completed by 
six internationally recognized PNTM experts) to gain consensus on annual preva-
lence of PNTM for each target country. A second-round of survey and use of the 
collaborative estimating process is currently being completed consisting of a chart 
review with physicians of a nationally representative sample (n= 30 per country) 
in a treatment refractory sub-group of PNTM patients to capture country specific 
treatment patterns and disease-related costs. “Refractory” is defined as at least 
one post-diagnostic positive culture despite 6 months of treatment. Results: We 
developed a rigorous methodology to identify a sub-group population to address the 
gap of actual disease prevalence by country. Publication reviewers have consistently 
and congruently confirmed the first-round epidemiologic study methodology met 
their respective required scientific standards. cOnclusiOns: Observational chart 
surveys in rare diseases that obtain a probability sample, a requirement for sample 
validity, can be used to provide essential disease-related metrics to populate market 
access and reimbursement evaluation procedures.
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Objectives: Systematic reviewers utilise filters to focus searches of electronic 
databases to identify specific study designs. Established, tested search filters are 
available from groups which regularly conduct reviews such as the Cochrane 
Group, SIGN and CADATH. Although studies in the real-world are not new, novel 
phrases such as real-world evidence (RWE) are increasingly used to identify obser-
vational studies. Currently available search filters for observational and non-
randomised studies do not adequately capture newer terms used. We have thus 
developed a method to identify frequently used MeSH terms in RWE studies and 
a search filter to include these terms. MethOds: A PubMed (MEDLINE®) search 
for RWE stated in the title/abstract was conducted. Articles with “real-world” and 
either “data”, “evidence” or “research” in the title or abstract were selected; Case 
Reports, Comment, Editorial, Letter, News were removed. MeSH terms associated 
with articles were analysed and frequency counted; those relating to study design 
or outcome reporting were chosen for inclusion in the search filter. Results: 
The MEDLINE® search identified 179 studies reporting RW and either data, evi-
dence or research in the title. Of the 179, 151 were publication types of interest. 
The most frequently used MeSH terms related to RWE identified were ‘Treatment 
Outcome’ (n= 30), ‘Evidence-based Medicine’ (n= 17), ‘Retrospective Studies’ (n= 15), 
‘Databases, Factual’ (n= 14), and ‘Time Factors’ (both n= 14). A search strategy was 
developed combining MeSH and free-text terms to identify RWE. cOnclusiOns: 
For every systematic review it is important to validate searches to ensure they are 
retrieving relevant studies; as new terminologies such as RWE are introduced to 
describe study design, reviewers need to adapt search filters. The method proposed 
allows searches to be adapted as terminologies are introduced and become more 
established.
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opportunity cost. These issues informed the development of a new checklist, which 
was subsequently applied. Critical appraisals of cost-effectiveness studies should 
consider the aforementioned issues to conclude on their quality and potential to 
inform decision-making. More research is needed how to quantify the opportunity 
costs of complex interventions, particularly when multiple sectors are affected.
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Health authorities may face a variety of options when deciding upon expanding 
their national pediatric immunization programs, ranging between an ad-hoc vac-
cine selection versus a targeted multi-year program to achieve efficiency goals. The 
vaccine portfolio management model allows the comparison of these two options 
over a fixed period of time. This optimization model is based on disease burden, vac-
cine impact and associated costs which are balanced against available vaccination 
budget and pre-defined public health priorities. Potential targets consist of reduc-
tion in disease events, or GP visits, or hospital occupancy rates, or deaths, or disease 
management cost. The model determines the optimal combination of vaccines 
selected per year, resulting in achieving the targeted public health outcome at the 
lowest annual budget. The financial results are then compared with those obtained 
after an ad-hoc selection of vaccines. The model was adapted for Japan in children 
up to 5 years old considering vaccines against pneumococcal disease, rotavirus, 
mumps and influenza disease based on published data. As an exemplary objective 
function we selected the reduction in hospital occupancy rates by 35% over a 5-year 
period. The portfolio model indicates that the optimal strategy consists of vacci-
nation against rotavirus, influenza, and mumps at 90% coverage and 55% vaccine 
coverage against pneumococcal disease, requiring an annual budget of 331 million 
EUR. In case of a lower budget, the vaccine selection would prioritize first rotavirus, 
followed by influenza, then mumps and pneumococcal vaccine (depending on the 
available budget) to reduce hospital occupancy rates to a maximum extent. With 
an ad-hoc selection of vaccine introduction, the budget required to achieve the 
same objective function may increase by more than10% each year compared with 
the previous approach. A vaccine portfolio management model can therefore sup-
port decision makers in making efficient choices when expanding their national 
pediatric immunization programs.
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bAckgROund: A health economic model was developed to compare treatment 
strategies for uterine fibroids (UF). Bleeding and pain were identified as the prin-
ciple disease-related symptoms affecting quality of life. Clinical trial data meas-
ured bleeding and pain through the pictorial bleeding assessment chart (PBAC) and 
visual analogue scale (VAS), respectively. However, the impact of PBAC and VAS on 
a single index measure of quality of life (QOL) is not widely studied. Objectives: 
Develop a symptom-driven utility function for patients with symptomatic UF, link-
ing incremental changes in PBAC and VAS to a single index measure of QOL that 
enables the calculation of quality-adjusted life-years (QALYs). MethOds: PBAC, 
VAS, and EQ-5D levels based on clinical trial data were used in the analysis. Two 
ordinary least squares regressions (Reg1 and Reg2) were conducted with EQ-5D 
(UK value set) as the dependent variable. Reg1 (N= 965) included PBAC and VAS 
as linear and quadratic terms to account for both linear and non-linear relation-
ships. Reg2 (N= 962) used a wider specification of independent variables including 
all regressors in Reg1 plus demographics and physical characteristics. Results: 
The regression coefficients from Reg1 were -0.0001 (p< 0.01) and -0.0044 (p< 0.01) 
for a one-unit change in the linear components of PBAC and VAS respectively, an 
intercept of 0.9164, and adjusted R2 of 0.3135. The quadratic coefficient estimates 
were very small, positive, and not statistically significant. An increase in the linear 
components of PBAC (VAS) of 300 (30) results in a 0.0355 (0.1308) unit decrease 
in EQ-5D QALY-weight. Differences in the coefficients of PBAC and VAS on EQ-5D 
between Reg1 and Reg2 were small. cOnclusiOns: The method described shows 
a pragmatic way to estimate QALY-weights in a health economic model that is 
responsive to incremental changes in patient symptoms for any intervention where 
PBAC and VAS data is available.
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Growing attention has been paid to patient-centric approach in clinical practice. 
The assessment of patient-reported outcomes (PROs) encourages communication 
between patients and physicians about goals of care. Post-marketing surveillance 
(PMS) is one of the available opportunities to collect large-scale, real-world data on 
patients’ experiences and PROs. Since PROs must be answered by patients them-
selves by definition, elderly patients may face specific challenges and need extra 
support to conduct a PRO survey as part of PMS. Various difficulties in conducting 
a PRO survey in PMS are expected, such as: 1) Additional support required at the 
participating sites for elderly patients. For example, they may need someone to read 
out the questions or record the responses for them without influencing patients’ 
responses 2) Lack of understanding of the value of PRO assessments for marketed 
